Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $350,839.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $15.80, for a total transaction of $350,839.00. Following the transaction, the chief executive officer now directly owns 663,456 shares of the company’s stock, valued at $10,482,604.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Saurabh Saha also recently made the following trade(s):

• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.53, for a total transaction of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.52, for a total value of $2,891,000.00.
• On Thursday, August 22nd, Saurabh Saha sold 506 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.23, for a total value of $6,188.38.
• On Tuesday, August 20th, Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $51,362.08.

Centessa Pharmaceuticals Stock Up 2.3 %

NASDAQ:CNTA opened at $15.50 on Friday. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27. Centessa Pharmaceuticals plc has a 12-month low of $5.58 and a 12-month high of $17.59. The stock’s fifty day simple moving average is $14.93 and its 200-day simple moving average is $11.45. The firm has a market capitalization of $1.56 billion, a P/E ratio of -10.67 and a beta of 1.46.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Equities research analysts expect that Centessa Pharmaceuticals plc will post -1.68 earnings per share for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC raised its position in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP lifted its holdings in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares in the last quarter. Sandia Investment Management LP acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at approximately $90,000. Finally, Fred Alger Management LLC acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at approximately $99,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CNTA has been the topic of several research reports. Jefferies Financial Group upped their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. B. Riley began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target for the company. BMO Capital Markets upped their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Oppenheimer reissued an “outperform” rating and issued a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Finally, Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $25.17.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.